Tian An Medicare has unveiled a conditional cash offer to repurchase up to 70 million shares—equivalent to approximately 6.48% of its issued capital—at HK$1.10 per share, representing a 15.79% premium to the 13 March 2026 closing price of HK$0.95.

The transaction, valued at HK$77.00 million, will be financed entirely from internal resources. The buy-back will proceed only if approved by a simple majority of shareholders at the Special General Meeting scheduled for 18 May 2026 in Hong Kong.

Assuming full acceptance, the company’s issued share base would shrink to about 1.01 billion shares, while public float would remain above the 25% threshold required by the Stock Exchange. The board expects the move to lift net asset value per share and provide shareholders with an optional liquidity event.

Following shareholder approval, the offer will remain open for 14 days, with settlement cheques dispatched within seven business days after the offer closes (targeted for 1 June 2026). Over 263 of the stock’s 273 trading days in the past year saw prices below the offer level, with the highest close at HK$1.14 and the lowest at HK$0.70.

Pelican Financial affirms Tian An Medicare has sufficient financial resources for the repurchase. The Independent Financial Adviser, Aurelius Corporate Finance, and the board’s Independent Committee have both recommended shareholders vote in favour of the offer.